Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

Evidence for efficacy is based on the results from the ADRIATIC study
17 Jan 2025
Immunotherapy
Small Cell Lung Cancer

On 4 December 2024, the US Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Efficacy was evaluated in ADRIATIC (NCT03703297), a randomised, double-blind, placebo-controlled study in 730 patients with LS-SCLC whose disease had not progressed following concurrent platinum-based chemotherapy and radiation therapy. Patients were randomised 1:1:1 to receive durvalumab as a single agent, durvalumab in combination with tremelimumab, or placebo.

The major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS) assessed by blinded independent central review for the comparison between durvalumab as a single agent and placebo. Durvalumab demonstrated a statistically significant OS improvement compared to placebo with a hazard ratio (HR) of 0.73 (95% confidence interval [CI] 0.57, 0.93; p-value 0.0104). The median OS was 55.9 months (95% CI 37.3, not reached) in the durvalumab arm and 33.4 months (95% CI 25.5, 39.9) in the placebo arm. Durvalumab also demonstrated a statistically significant PFS improvement compared to placebo with HR of 0.76 (95% CI 0.61, 0.95; p-value 0.0161). The median PFS was 16.6 months (95% CI 10.2, 28.2) and 9.2 months (95% CI 7.4, 12.9) in the durvalumab and placebo arms, respectively.

The most common adverse reactions (≥20%) were pneumonitis or radiation pneumonitis and fatigue.

The recommended durvalumab dose is 1,500 mg every 4 weeks for patients with a body weight of ≥30 kg and 20 mg/kg every 4 weeks for patients with a body weight of <30 kg until disease progression or unacceptable toxicity or a maximum of 24 months.
This review was conducted under Project Orbis, an initiative of the FDA’s Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration, the Brazilian Health Regulatory Agency, Health Canada, and Swissmedic. The European Medicines Agency was an official observer of this review. The application reviews may be ongoing at the other regulatory agencies.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review and breakthrough designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.